ReviewFrontiers in cell and developmental biology2023
Wharton's jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications.
Review in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the efficacy of mesenchymal stem cells for diabetic neuropathy: A systematic review and meta-analysis of preclinical studies.Frontiers in bioengineering and biotechnology · 2024Pooled it
- Safety and efficiency of Wharton's Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study.World journal of stem cells · 2024Trial
- Cell-Free Wharton's Jelly-Derived MSC Secretome in a Polymeric Carrier for Refractory Chronic Wounds: Two Cases.Bioengineering (Basel, Switzerland) · 2026Article
- Combined Mesenchymal Stem Cells and Low-Energy Shock Wave Therapy Significantly Reduced Inflammation, Oxidative Stress and Preserved Podocytes in Diabetic Nephropathy.Life (Basel, Switzerland) · 2026Article
- Secretome Derived from Umbilical Cord Mesenchymal Stem Cells as a Therapeutic Approach for Osteoarthritis: Insights from In Vitro, In Vivo, and Clinical Evidence.Cell biochemistry and biophysics · 2026Review
- Fibroblast stress responses to 3D-spheroid culture and thermal challenge, and stem-cell secretome-mediated repair: an exploratory in vitro investigation.Odontology · 2026Article
- Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton's Jelly Mesenchymal Stem Cells in the Orchestrum.Brain sciences · 2026Review
- Article
- Integrating Cells, Biomaterials, and Advanced Engineering for Next-Generation Peripheral Nerve Repair.Cells, tissues, organs · 2026Review
- "Next-Generation Cord Blood Expansion: Bridging the Cell Dose Gap with Bioengineered Niches and Clinical Breakthroughs".Stem cell reviews and reports · 2026Review
- Article
- Donor age and sex program MSC secretome signaling: a quadrant framework for precision therapy.Stem cell research & therapy · 2026Article
- Obtention of conditional media from Wharton’s gelatin mesenchymal stromal cells in a dynamic culture systemBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Wharton's jelly mesenchymal stem cell-secretome enhances skin rejuvenation via ApoA4 and SERPINH1.Regenerative therapy · 2026Article
- Critical evaluation of compositions and clinical relevance of Wharton's jelly-derived biologics.Journal of translational medicine · 2026Review
- Intradermal Application of Allogenic Wharton's Jelly Mesenchymal Stem Cells for Chronic Post-Thoracotomy Wound in an Elderly Patient After Coronary Artery Bypass Grafting: Clinical Case with Brief Literature Review.Diseases (Basel, Switzerland) · 2026Article
- The antimicrobial potential of the secretome from Wharton's jelly mesenchymal stem cells in the context of regenerative medicine: anFrontiers in immunology · 2026Article
- Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.International journal of nanomedicine · 2026Review
- From Biological Waste to Therapeutic Resources: A Comprehensive Review of Stem Cell Sources, Characterization, and Biomedical Potentials.Stem cell reviews and reports · 2026Review
- Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy.Stem cell reviews and reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence indicates that most primary Wharton's jelly mesenchymal stem cells (WJ-MSCs) therapeutic potential is due to their paracrine activity, i.e., their ability to modulate their microenvironment by releasing bioactive molecules and factors collectively known as secretome. These bioactive molecules and factors can either be released directly into the surrounding microenvironment or can be embedded within the membrane-bound extracellular bioactive nano-sized (usually 30-150 nm) messenger particles or vesicles of endosomal origin with specific route of biogenesis, known as exosomes or carried by relatively larger particles (100 nm-1 μm) formed by outward blebbing of plasma membrane called microvesicles (MVs); exosomes and MVs are collectively known as extracellular vesicles (EVs). The bioactive molecules and factors found in secretome are of various types, including cytokines, chemokines, cytoskeletal proteins, integrins, growth factors, angiogenic mediators, hormones, metabolites, and regulatory nucleic acid molecules. As expected, the secretome performs different biological functions, such as immunomodulation, tissue replenishment, cellular homeostasis, besides possessing anti-inflammatory and anti-fibrotic effects. This review highlights the current advances in research on the WJ-MSCs' secretome and its prospective clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.